- Category: Experimental HCV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
Interferon-free treatment using a single daily combination pill containing sofosbuvir plus ledipasvir demonstrated potent anti-HCV activity and was generally well-tolerated in a primarily African-American inner city population with genotype 1a hepatitis C, researchers reported at the recent AASLD Liver Meeting in Washington, DC. Adding a third drug resulted in high early post-treatment response rates with shorter treatment.